Inventiva Pharma

[And its gone!]

De lucht is uit het ballonnetje. vals alarm.

[NewB76]

Technisch is de gap naar beneden gesloten .
Verdere stijging is terug mogelijk , we zullen zien morgen ?
Welke fondsen zorgden voor deze koers-opstoot ? en waarom ?

[NewB76]

dubbele post

[Lama Daila]

[Lama Daila]

[Lama Daila]

[Lama Daila]

[NewB76]

De uitnodiging tot de Fireside chat van 17 oktober is precies belangrijk geweest !

[NewB76]

Oct 31 (Reuters) - Inventiva SA :
* INVENTIVA PROVIDES AN UPDATE ON THE DEVELOPMENT OF CEDIROGANT BY ABBVIE
* COMPANY'S CASH RUNWAY, INCLUDING IS NOT IMPACTED BY DISCONTINUATION OF CEDIROGANT CLINICAL PROGRAM
* CASH RUNWAY SHOULD ALLOW TO FUND AS PREVIOUSLY ANNOUNCED OPERATIONS THROUGH Q4 2023
* INVENTIVA'S R&D CAPABILITIES AND OBJECTIVES REMAIN UNALTERED

[NewB76]

Daix (France), Long Island City (New York, United States), October 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that AbbVie communicated during their third- quarter financial results1 on Friday October 28th, that they decided to stop the development of cedirogant (ABBV- 157), an oral RORγ inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases, following the analysis of a recently concluded nonclinical toxicology study.